A pharmacoeconomic analysis of the impact of therapeutic drug monitoring in adult patients with generalized tonic-clonic epilepsy

British Journal of Clinical Pharmacology

Volumn 52, Issue 2, 2001, Pages 193-195

  Rane, C T ^a   Dalvi, S S ^a   Gogtay, N J ^a   Shah, P U ^b   Kshirsagar, N A ^a,b  

^a BYL NAIR CHARITABLE HOSPITAL   (India)

^b KEM HOSPITAL   (India)

Author keywords

Epilepsy; Pharmacoeconomics; Therapeutic drug monitoring

Indexed keywords

ANTICONVULSIVE AGENT;

ADULT; ARTICLE; CALCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE DURATION; DRUG MONITORING; ECONOMIC EVALUATION; FEMALE; GRAND MAL EPILEPSY; HOSPITAL COST; HUMAN; MALE; PRIORITY JOURNAL; REMISSION; SIDE EFFECT;

ADOLESCENT; ADULT; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DRUG MONITORING; DRUG THERAPY; EPILEPSY, TONIC-CLONIC; FEMALE; HOSPITALIZATION; HUMANS; MALE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SEIZURES;

EID: 0034826737     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0306-5251.2001.01436.x     Document Type: Article

References (6)

1. The role of therapeutic drug monitoring in improving cost-effectiveness of anticonvulsant therapy
2. Pharmacoeconomics and therapeutic drug monitoring
3. Therapeutic drug monitoring in a developing country: An overview
4. Analysis of a clinically important interaction between phenytoin and shankhapushpi, an ayurvedic preparation
5. Simultaneous HPLC measurements of phenobarbitone, phenytoin and carbamazepine from plasma samples
6. Best practice in therapeutic drug monitoring